Colossal Biosciences Reportedly Seeks Funding at $20B–$30B Valuation

Colossal Biosciences, the startup known for its ambitious efforts to revive extinct species, is reportedly in discussions to raise a new round of funding at a valuation between $20 billion and $30 billion. The talks come around 16 months after the company attracted global attention for its de-extinction programme and achieved a reported valuation of $10.2 billion.

According to reports, it remains unclear how much capital the five-year-old company plans to secure or which investors may lead the financing. However, the company has reportedly begun generating revenue over the past year, marking an important milestone as it expands beyond research into commercial applications.

Multiple revenue streams support growth strategy.

Chief executive and co-founder Ben Lamm has previously outlined three potential revenue streams for the business. One involves offering thecompany’ss conservation technologies to governments, including the United States and the United Arab Emirates, which has already invested $60 million in Colossal.

The company has also created several spin-off businesses built around technologies developed during its research. These include Breaking, which focuses on plastic decomposition, Form Bio, a computational biology platform that has raised $30 million, and Astromech, an AI-powered predictive modelling company for life sciences that received a reported $2 billion valuation earlier this year.

Expanding scientific and conservation initiatives

Operating from a 55,000-square-foot headquarters in Dallas, Colossal continues to broaden the use of its core biotechnology. In April, it added the bluebuck antelope to its growing list of de-extinction targets, while its nonprofit Colossal Foundation recently partnered with the University of Tasmania to help protect Tasmanian devils from a contagious facial cancer.

Lamm has also said the company intends to spin off its artificial animal womb technology, which could eventually support human fertility treatments. He recently indicated that the technology may be ready next year.

Long-term vision extends beyond de-extinction.

If Colossal succeeds in returning extinct species such as the woolly mammoth and the dodo to their native habitats, the company believes it could eventually generate revenue through biodiversity credits, a market-based system similar to carbon credits that rewards conservation efforts.

The latest fundraising discussions come as investor interest continues to grow across deep-tech sectors, including longevity research, advanced biotechnology, and alternative energy, positioning Colossal among the industry’s most closely watched startups.